Ono Pharmaceutical said on October 24 that it has filed a lawsuit against MSD, claiming that the US-based firm’s Keytruda (pembrolizumab), approved in Japan late last month, infringes its patent related to anti-PD-1 antibodies. The lawsuit was filed with the…
To read the full story
Related Article
- BMS-Ono Pair, Merck Settle Keytruda Patent Suits
January 23, 2017
BUSINESS
- Shionogi to Buy Tanabe’s Edaravone Biz for US$2.5 Billion Upfront
December 23, 2025
- Asahi Kasei to Relocate R&D Base to Shonan iPark in January 2027
December 23, 2025
- Daiichi Begins Global PIII of Enhertu in Adjuvant Endometrial Cancer Use
December 23, 2025
- Enhertu Wins US Breakthrough Tag in Post-Neoadjuvant HER2 Breast Cancer
December 23, 2025
- Teikoku to Market Medipost’s Knee OA Cell Therapy in Japan
December 22, 2025
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…





